Last updated: 2026-09-16 12:10:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
XBiotech Inc. (XBIT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.18, with a market capitalisation of $66.16M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.09 to $3.44. This page covers its latest market performance, valuation, price trends and company information.
$66.16M | |
$2.18 | |
$32.50 | |
$2.09 | |
$2.19 | |
-- | |
40.69K | |
-- | |
$3.44 | |
$2.09 | |
-- | |
-- |
XBiotech Inc. (XBIT) is trading at $2.18 in pre-market trading as of 2026-09-16 11:50:00, down 0.64% ($0.01) from the previous close of $2.20
Pre-market trading shows how investors are pricing XBIT before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, XBiotech Inc. (XBIT) moved from $2.20 to $2.18, representing a decline of 0.86% ($0.02).
The stock traded between $2.15 and $2.27 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 39.95 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 6.7%
XBIT is currently trading at $2.18, placing it 6.7% of the way from its 52-week low of $2.09 to its 52-week high of $3.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 87 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of XBiotech Inc. (XBIT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.